User login
In this supplement you will learn about:
- The formulation characteristics of calcipotriene-betamethasone dipropionate aerosol foam (Cal/BD-AF)
- The efficacy and safety of Cal/BD-AF
- The results of Phase III clinical trials completed with Cal/BD-AF
Author
James Q. Del Rosso, DO, FAOCD, FAAD
Adjunct Clinical Professor (Dermatology), Touro University Nevada, Henderson, Nevada
Lakes Dermatology and Del Rosso Dermatology Research Center, Las Vegas, Nevada
Dr. Del Rosso discloses that he is a consultant, speaker, and researcher for LEO Pharma Inc. Related to this subject area he is also a consultant, speaker, and/or researcher for Aqua Pharmaceuticals/Almirall, S.A.; Bayer AG; Celgene Corporation; Galderma Laboratories, L.P.; Genentech, Inc.; Novan, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc. /Anacor Pharmaceuticals, Inc.; PharmaDerm; Promius Pharma, LLC; Sun Pharmaceutical Industries, Ltd.; and Valeant Pharmaceuticals International, Inc.
In this supplement you will learn about:
- The formulation characteristics of calcipotriene-betamethasone dipropionate aerosol foam (Cal/BD-AF)
- The efficacy and safety of Cal/BD-AF
- The results of Phase III clinical trials completed with Cal/BD-AF
Author
James Q. Del Rosso, DO, FAOCD, FAAD
Adjunct Clinical Professor (Dermatology), Touro University Nevada, Henderson, Nevada
Lakes Dermatology and Del Rosso Dermatology Research Center, Las Vegas, Nevada
Dr. Del Rosso discloses that he is a consultant, speaker, and researcher for LEO Pharma Inc. Related to this subject area he is also a consultant, speaker, and/or researcher for Aqua Pharmaceuticals/Almirall, S.A.; Bayer AG; Celgene Corporation; Galderma Laboratories, L.P.; Genentech, Inc.; Novan, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc. /Anacor Pharmaceuticals, Inc.; PharmaDerm; Promius Pharma, LLC; Sun Pharmaceutical Industries, Ltd.; and Valeant Pharmaceuticals International, Inc.
In this supplement you will learn about:
- The formulation characteristics of calcipotriene-betamethasone dipropionate aerosol foam (Cal/BD-AF)
- The efficacy and safety of Cal/BD-AF
- The results of Phase III clinical trials completed with Cal/BD-AF
Author
James Q. Del Rosso, DO, FAOCD, FAAD
Adjunct Clinical Professor (Dermatology), Touro University Nevada, Henderson, Nevada
Lakes Dermatology and Del Rosso Dermatology Research Center, Las Vegas, Nevada
Dr. Del Rosso discloses that he is a consultant, speaker, and researcher for LEO Pharma Inc. Related to this subject area he is also a consultant, speaker, and/or researcher for Aqua Pharmaceuticals/Almirall, S.A.; Bayer AG; Celgene Corporation; Galderma Laboratories, L.P.; Genentech, Inc.; Novan, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc. /Anacor Pharmaceuticals, Inc.; PharmaDerm; Promius Pharma, LLC; Sun Pharmaceutical Industries, Ltd.; and Valeant Pharmaceuticals International, Inc.